Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%
Other

Rocket Doctor's Treatment receives $2M (U.S.) grant

By The Northwire Desk — AI Analysis Oct 15, 2025 · 16:57 AIDR · 0.72 Rocket Doctor AI Inc
AIDR · Price

Executive Summary

  • Rocket Doctor AI Inc.’s U.S. subsidiary, Treatment.com Inc., received a $2 million NIH Small Business Innovation Research Phase 2 grant to advance culturally‑sensitive family medical history collection using AI.
  • The two‑year award includes over $500,000 earmarked for further development and integration of the technology across commercial platforms.
  • Collaboration with Rush River Research will expand the project’s focus on African American communities while generating insights applicable to all families.

Key Details

  • Grant Amount & Duration: $2 million (U.S.) over two years; Phase 2 award following a competitive peer‑review process.
  • Funding Allocation: More than $500,000 designated for additional development and integration work by Treatment.com Inc. with Rush River Research.
  • Project Scope: Enhances AI‑driven collection of culturally sensitive family health histories; aims to improve diagnosis, treatment, preventive care, early screening, and lifestyle interventions.
  • Target Population: Primarily African American communities (higher mortality from heart disease, stroke, cancer, diabetes), with broader applicability to all families.
  • Collaborators: Treatment.com Inc. (Rocket Doctor AI subsidiary) and Rush River Research; both contributed technical, design, and research expertise in Phase 1 and will continue into Phase 2.
  • Strategic Importance: Supports commercialization of AI health‑history tools, leveraging Rocket Doctor’s Global Library of Medicine (GLM) and AI platform to expand access to high‑quality care.

Notable Quotes

“We’re excited to deepen our collaboration with Rush River Research and apply our next‑generation AI technologies to make a tangible difference across all communities.” – Dr. Kevin Peterson, Founder & Chief Medical Officer, Rocket Doctor AI Inc.

“Our goal is to help families have informed conversations about their family health history and better understand the important role it plays in their overall well‑being.” – Julie Lundstrom, Co‑founder, Rush River Research.

Read the original news release →

More from Rocket Doctor AI Inc

Jun 30, 2026 · 08:00

Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members

M&A / Property Jun 23, 2026 · 08:00

AI-driven telemedicine platform expanding U.S. payer network, but burning cash with a going concern warning.

M&A / Property Jun 18, 2026 · 08:00

AI-driven telehealth platform scaling U.S. payer network, but burning cash and diluting equity to fund marketing.

M&A / Property Jun 16, 2026 · 08:00

AI-driven telehealth platform scaling U.S. payer access while burning cash to fund growth and R&D.

Other Jun 08, 2026 · 08:00

Rocket Doctor AI Launches a Strategic Marketing Partnership with Rick Ware Racing and FINTEKK AP for the 2026 NASCAR Cup Series, NHRA (National Hot Rod Association), World Supercross Championship, AFT (AMA - American Flat Track) and other Nationally telev

M&A / Property Jun 02, 2026 · 08:00

AI Virtual Care Platform Accelerates U.S. Visits and Secures Cash Runway, But Margin Compression and Going Concern Doubts Loom

Earnings